Penserra Capital Management LLC Beam Therapeutics Inc. Transaction History

Penserra Capital Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$23.01 - $32.46 $64,266 - $90,660	2,793 Added 36.02%	10,548 $253,000
Q2 2023 Aug 11, 2023	BUY	$29.32 - $35.99 $41,194 - $50,565	1,405 Added 22.13%	7,755 $247,000
Q1 2023 Apr 24, 2023	BUY	$30.15 - $48.79 $2,412 - $3,903	80 Added 1.28%	6,350 $194,000
Q4 2022 Feb 13, 2023	SELL	$36.73 - $51.6 $123,743 - $173,840	-3,369 Reduced 34.95%	6,270 $245,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $273,078 - $482,537	6,863 Added 247.23%	9,639 $459,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $32,129 - $67,099	1,076 Added 63.29%	2,776 $107,000
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $91,341 - $139,672	1,700 New	1,700 $97,000
Q4 2021 Feb 15, 2022	SELL	$68.02 - $99.06 $103,730 - $151,066	-1,525 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $8,437 - $13,360	100 Added 7.02%	1,525 $132,000
Q2 2021 Aug 12, 2021	BUY	$64.12 - $128.71 $7,373 - $14,801	115 Added 8.78%	1,425 $183,000
Q1 2021 May 13, 2021	SELL	$71.28 - $120.75 $1,782 - $3,018	-25 Reduced 1.87%	1,310 $104,000
Q4 2020 Feb 12, 2021	BUY	$22.24 - $95.63 $29,690 - $127,666	1,335 New	1,335 $108,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.